阿普司特治疗银屑病关节炎：一篇综述
Apremilast in the treatment of psoriatic arthritis: a perspective review.
作者信息
Reed Michael, Crosbie David
机构信息
Department of Rheumatology, Queen Elizabeth University Hospital, UK.
Department of Rheumatology, Queen Elizabeth University Hospital, 1345 Govan Road, Glasgow G51 4TF, UK.
出版信息
Ther Adv Musculoskelet Dis. 2017 Feb;9(2):45-53. doi: 10.1177/1759720X16673786. Epub 2017 Jan 20.
Abstract
Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4). Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis. Established therapeutic options have variable effectiveness across the different domains of psoriatic disease. Whilst biologic therapies have proven to be of significant benefit to many patients, not all patients respond, and others are not eligible or do not tolerate biologic therapy. We review the mechanism of action, pharmacokinetics and clinical trial data with regards to both efficacy and safety for apremilast and consider where this new treatment may be positioned in the treatment of PsA.
摘要
阿普米司特是一种口服活性小分子，可抑制磷酸二酯酶-4（PDE4）。临床试验已证明其在银屑病关节炎（PsA）和银屑病中的疗效和安全性。现有的治疗方案在银屑病疾病的不同领域效果各异。虽然生物疗法已被证明对许多患者有显著益处，但并非所有患者都有反应，其他患者不符合条件或不耐受生物疗法。我们回顾了阿普米司特的作用机制、药代动力学以及关于疗效和安全性的临床试验数据，并考虑这种新疗法在PsA治疗中的定位。
相似文献
1
Apremilast in the treatment of psoriatic arthritis: a perspective review.阿普司特治疗银屑病关节炎：一篇综述
Ther Adv Musculoskelet Dis. 2017 Feb;9(2):45-53. doi: 10.1177/1759720X16673786. Epub 2017 Jan 20.
2
Drug safety evaluation of apremilast for treating psoriatic arthritis.阿普司特治疗银屑病关节炎的药物安全性评估
Expert Opin Drug Saf. 2015 Jun;14(6):979-85. doi: 10.1517/14740338.2015.1031743. Epub 2015 Mar 31.
3
Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.阿普司特：一种用于治疗银屑病关节炎的磷酸二酯酶4抑制剂。
Rheumatol Ther. 2014 Dec;1(1):1-20. doi: 10.1007/s40744-014-0005-4. Epub 2014 Dec 9.
4
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.阿普米司特：用于银屑病和银屑病关节炎的治疗。
Drugs. 2017 Mar;77(4):459-472. doi: 10.1007/s40265-017-0709-1.
5
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.阿普米拉斯治疗银屑病关节炎患者的III期随机对照试验：PALACE 2试验结果
J Rheumatol. 2016 Sep;43(9):1724-34. doi: 10.3899/jrheum.151376. Epub 2016 Jul 15.
6
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.银屑病关节炎和银屑病患者的定制治疗方案：已确立及新型生物制剂和小分子疗法综述
Rheumatol Int. 2016 May;36(5):603-12. doi: 10.1007/s00296-016-3436-0. Epub 2016 Feb 18.
7
Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.阿普司特：一种用于治疗银屑病关节炎的磷酸二酯酶4（PDE4）抑制剂。
Expert Opin Pharmacother. 2015 May;16(7):1099-108. doi: 10.1517/14656566.2015.1034107. Epub 2015 Apr 11.
8
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.阿普米司特：用于治疗银屑病和银屑病关节炎的药物评价。
Drugs. 2015 Aug;75(12):1393-403. doi: 10.1007/s40265-015-0439-1.
9
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.银屑病关节炎患者接受阿普米司特治疗的长期经验：来自 PALACE 1-3 汇总分析的 5 年结果。
Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3.
10
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).阿普司特，一种口服磷酸二酯酶4抑制剂，用于治疗银屑病关节炎伴皮肤受累患者：一项III期随机对照试验（PALACE 3）。
Ann Rheum Dis. 2016 Jun;75(6):1065-73. doi: 10.1136/annrheumdis-2015-207963. Epub 2016 Jan 20.
引用本文的文献
1
Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease.利妥昔单抗、阿普米司特和乌帕替尼作为具有不同作用机制的选定生物类似药和靶向合成改善病情抗风湿药：它们目前在减缓疾病进展方面的应用。
J Clin Med. 2025 Apr 10;14(8):2605. doi: 10.3390/jcm14082605.
2
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis.生物制剂和靶向合成疾病修正抗风湿药物在银屑病关节炎患者中的真实世界药物生存情况。
Drugs Aging. 2024 Aug;41(8):685-697. doi: 10.1007/s40266-024-01136-7. Epub 2024 Aug 6.
3
Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPsA study).甲氨蝶呤与阿普米司特治疗银屑病关节炎的比较：一项单盲随机对照试验（APREMEPsA 研究）。
Rheumatol Int. 2023 May;43(5):841-848. doi: 10.1007/s00296-023-05315-4. Epub 2023 Mar 24.
4
Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database.初治的银屑病关节炎患者使用阿普米拉斯与甲氨蝶呤起始治疗的生物制剂启用率：基于美国医保索赔数据库的1年回顾性分析
Open Access Rheumatol. 2022 Jun 15;14:123-132. doi: 10.2147/OARRR.S342123. eCollection 2022.
5
Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells.阿普米司特通过抑制 PDE4 来减轻皮肤纤维化，其作用机制是直接抑制 M1 和 T 细胞的激活。
Acta Pharmacol Sin. 2022 Feb;43(2):376-386. doi: 10.1038/s41401-021-00656-x. Epub 2021 Apr 13.
6
Psoriatic arthritis with skin lesions localized to the scalp: A case report.皮肤病变局限于头皮的银屑病关节炎：一例报告。
J Gen Fam Med. 2020 Jul 8;21(6):264-267. doi: 10.1002/jgf2.358. eCollection 2020 Nov.
7
An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis.临床医生关于治疗银屑病关节炎生物制剂的最新进展
Biologics. 2020 Aug 20;14:53-75. doi: 10.2147/BTT.S260754. eCollection 2020.
8
Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin.希腊银屑病关节炎患者的临床、血清学和免疫学特征：白细胞介素-17、白细胞介素-23和硬化蛋白的作用
Mediterr J Rheumatol. 2020 Jun 10;31(2):235-236. doi: 10.31138/mjr.31.2.235. eCollection 2020 Jun.
9
Efficacy of Novel Pyrazolone Phosphodiesterase Inhibitors in Experimental Mouse Models of Trypanosoma cruzi.新型吡唑啉酮磷酸二酯酶抑制剂在克氏锥虫实验小鼠模型中的疗效
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00414-20.
10
IL-12/IL-23p40 identified as a downstream target of apremilast in models of arthritis.在关节炎模型中，白细胞介素-12/白细胞介素-23 p40被确定为阿普司特的下游靶点。
Ther Adv Musculoskelet Dis. 2019 Feb 22;11:1759720X19828669. doi: 10.1177/1759720X19828669. eCollection 2019.
本文引用的文献
1
Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.对肿瘤坏死因子抑制剂反应不足的银屑病关节炎患者中后续生物制剂疗效的间接比较：一项荟萃分析。
Clin Rheumatol. 2016 Jul;35(7):1795-803. doi: 10.1007/s10067-016-3204-2. Epub 2016 Feb 6.
2
Emerging drugs for psoriatic arthritis.银屑病关节炎的新兴药物。
Expert Opin Emerg Drugs. 2016;21(1):69-79. doi: 10.1517/14728214.2016.1146679. Epub 2016 Feb 15.
3
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.银屑病关节炎研究与评估小组 2015 年银屑病关节炎治疗建议。
Arthritis Rheumatol. 2016 May;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.
4
An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.阿达木单抗、甲氨蝶呤和阿普米司特治疗初治银屑病关节炎患者的间接比较及每应答者成本分析。
Curr Med Res Opin. 2016;32(4):721-9. doi: 10.1185/03007995.2016.1140026. Epub 2016 Jan 25.
5
The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis.阿普司他与甲氨蝶呤联合给药对类风湿关节炎和银屑病关节炎患者的药代动力学影响。
Clin Pharmacol Drug Dev. 2014 Nov;3(6):456-465. doi: 10.1002/cpdd.109. Epub 2014 May 8.
6
Simple clinical indicators for early psoriatic arthritis detection.早期银屑病关节炎检测的简单临床指标。
Springerplus. 2014 Dec 22;3:759. doi: 10.1186/2193-1801-3-759. eCollection 2014.
7
Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.阿普司特治疗银屑病关节炎患者的III期随机对照试验的长期（52周）结果。
J Rheumatol. 2015 Mar;42(3):479-88. doi: 10.3899/jrheum.140647. Epub 2015 Jan 15.
8
An update on disease modifying antirheumatic drugs.改善病情抗风湿药物的最新进展。
Inflamm Allergy Drug Targets. 2014;13(4):249-61. doi: 10.2174/187152811304140915152102.
9
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.在一项口服磷酸二酯酶 4 抑制剂阿普米司特的 3 期随机、安慰剂对照试验中治疗银屑病关节炎。
Ann Rheum Dis. 2014 Jun;73(6):1020-6. doi: 10.1136/annrheumdis-2013-205056. Epub 2014 Mar 4.
10
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.阿普米司特治疗中重度银屑病的疗效：一项随机对照试验。
Lancet. 2012 Aug 25;380(9843):738-46. doi: 10.1016/S0140-6736(12)60642-4. Epub 2012 Jun 29.
Zotero 插件